About
Drugs Derived from Natural Compounds
PsygaBio is a drug discovery company focused on developing therapeutics derived from natural compounds.
Using Cannasoul's proprietary analytical platform, PsygaBio's data-driven approach, know-how, and clinical trial framework support active compound identification and development, from mushroom cultivation and extraction to clinically approved formulations.
PsygaBio, in partnership with Cannasoul Analytics, aims to exploit the diversity found in the psychedelic mushroom realm to identify active compounds and formulations for therapeutic benefits.
PsygaBio is a subsidiary of Cannasoul Analytics.
Identity
| Name | PsygaBio |
|---|---|
| Slug | psygabio |
| Type / kind | startup |
| Source _id | h1kfqiDq8UkzpyvkvoBfD2CvWSzhsa7WNJXWxDAnDbQIrt3qEQcpz4 |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | Caesarea |
| HQ address | Tarshish St 5, Caesarea, 3079822, Israel |
Web & social
| Website | https://cannasoul.co.il/psyga-bio/ |
|---|---|
| https://www.linkedin.com/company/86858667 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyMedical CannabisDrugs Discovery & Development
Technologies
BiologicalsCellsHerbals
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business models
B2B
Tags
geneticspharmaceuticals
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}